$NMTC
NEUROONE MEDICAL TECHNOLOGIES Corp Stock $nmtc

$nmtc Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000121390024068633 Filed on August 14, 2024

Income Statement

Concept	2024 Q3	2024 Q2	2023 Q2
Revenue		$825.8K	$629.9K
YoY Change		31.1%	1865.45%
Cost Of Revenue		$543.9K	$386.2K
YoY Change		40.82%	904.21%
Gross Profit		$281.9K	$243.7K
YoY Change		15.68%	-3899.56%
Gross Profit Margin		34.13%	38.68%
Selling, General & Admin		$1.881M	$1.862M
YoY Change		1.0%	21.75%
% of Gross Profit		667.36%	764.32%
Research & Development		$1.195M	$1.892M
YoY Change		-36.84%	54.36%
% of Gross Profit		423.84%	776.27%
Depreciation & Amortization		$57.53K	$51.38K
YoY Change		11.97%	98.16%
% of Gross Profit		20.41%	21.09%
Operating Expenses		$3.076M	$3.754M
YoY Change		-18.06%	36.26%
Operating Profit		-$2.794M	-$3.510M
YoY Change		-20.41%	27.12%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net		$26.38K	$41.46K
YoY Change		-36.38%	2324.56%
Pretax Income		-$2.768M	-$3.469M
YoY Change		-20.22%	25.69%
Income Tax
% Of Pretax Income
Net Earnings		-$2.768M	-$3.469M
YoY Change		-20.22%	25.69%
Net Earnings / Revenue		-335.14%	-550.68%
Basic Earnings Per Share		-$0.10	-$0.20
Diluted Earnings Per Share		-$0.10	-$0.20
COMMON SHARES
Basic Shares Outstanding	30.81M shares	27.52M shares	17.56M shares
Diluted Shares Outstanding		27.35M shares	17.58M shares

Balance Sheet

Concept	2024 Q3	2024 Q2	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments		$1.620M	$3.083M
YoY Change		-47.46%	-69.71%
Cash & Equivalents	$1.460M	$1.620M	$3.083M
Short-Term Investments			$0.00
Other Short-Term Assets		$261.5K	$278.8K
YoY Change		-6.21%	-6.0%
Inventory	$2.635M	$1.793M	$1.517M
Prepaid Expenses			$278.8K
Receivables	$176.6K	$410.6K
Other Receivables		$0.00	$0.00
Total Short-Term Assets	$4.631M	$4.085M	$4.879M
YoY Change	-36.67%	-16.26%	-55.36%
LONG-TERM ASSETS
Property, Plant & Equipment	$416.8K	$472.5K	$586.9K
YoY Change	-20.72%	-19.49%	86.16%
Goodwill
YoY Change
Intangibles	$67.26K	$72.84K	$95.16K
YoY Change	-24.91%	-23.45%	-19.0%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$739.0K	$827.2K	$879.4K
YoY Change	-5.78%	-5.94%	37.04%
TOTAL ASSETS
Total Short-Term Assets	$4.631M	$4.085M	$4.879M
Total Long-Term Assets	$739.0K	$827.2K	$879.4K
Total Assets	$5.370M	$4.913M	$5.758M
YoY Change	-33.68%	-14.68%	-50.24%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.029M	$759.3K	$958.8K
YoY Change	50.23%	-20.81%	194.99%
Accrued Expenses	$1.184M	$931.7K	$789.1K
YoY Change	6.91%	18.07%	61.95%
Deferred Revenue
YoY Change
Short-Term Debt		$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.213M	$1.691M	$1.748M
YoY Change	23.46%	-3.26%	114.59%
LONG-TERM LIABILITIES
Long-Term Debt		$0.00	$0.00
YoY Change
Other Long-Term Liabilities		$209.9K	$88.92K
YoY Change		136.07%	-35.55%
Total Long-Term Liabilities		$209.9K	$88.92K
YoY Change		136.07%	-35.55%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.213M	$1.691M	$1.748M
Total Long-Term Liabilities		$209.9K	$88.92K
Total Liabilities	$4.548M	$1.901M	$1.837M
YoY Change	146.11%	3.49%	92.85%
SHAREHOLDERS EQUITY
Retained Earnings	-$75.00M	-$71.70M	-$59.55M
YoY Change	19.64%	20.4%	20.42%
Common Stock	$30.82K	$27.85K	$17.86K
YoY Change	28.78%	55.9%	10.29%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$822.0K	$3.012M	$3.921M
YoY Change
Total Liabilities & Shareholders Equity	$5.370M	$4.913M	$5.758M
YoY Change	-33.68%	-14.68%	-50.24%

Cashflow Statement

Concept	2024 Q2	2023 Q2
OPERATING ACTIVITIES
Net Income	-$2.768M	-$3.469M
YoY Change	-20.22%	25.69%
Depreciation, Depletion And Amortization	$57.53K	$51.38K
YoY Change	11.97%	98.16%
Cash From Operating Activities	-$2.360M	-$2.940M
YoY Change	-19.72%	11.52%
INVESTING ACTIVITIES
Capital Expenditures	$14.80K	$139.3K
YoY Change	-89.37%	-356.85%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$1.000M
YoY Change	-100.0%
Cash From Investing Activities	-$14.80K	$860.7K
YoY Change	-101.72%	-1687.13%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.561M	1.561M
YoY Change	-0.02%
NET CHANGE
Cash From Operating Activities	-2.360M	-2.940M
Cash From Investing Activities	-14.80K	860.7K
Cash From Financing Activities	1.561M	1.561M
Net Change In Cash	-814.7K	-518.7K
YoY Change	57.06%	-80.72%
FREE CASH FLOW
Cash From Operating Activities	-$2.360M	-$2.940M
Capital Expenditures	$14.80K	$139.3K
Free Cash Flow	-$2.375M	-$3.080M
YoY Change	-22.87%	19.25%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q2	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2024Q2	nmtc	Revenue From Collaboration RevenueFromCollaboration		usd
CY2023Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2024Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2023Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2024Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.20
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.35
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.52
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17578871	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	25746503	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	27352660	shares
CY2024Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2023Q2	nmtc	Stock Issued During Period Value Restricted Stock Unit Gross StockIssuedDuringPeriodValueRestrictedStockUnitGross		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-40439
	dei	Entity Registrant Name EntityRegistrantName	NeuroOne Medical Technologies Corporation
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-0863354
	dei	Entity Address Address Line1 EntityAddressAddressLine1	7599 Anagram Drive
	dei	Entity Address City Or Town EntityAddressCityOrTown	Eden Prairie
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MN
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	55344
	dei	City Area Code CityAreaCode	952
	dei	Local Phone Number LocalPhoneNumber	426-1383
	dei	Security12b Title Security12bTitle	Common stock, $0.001 par value
	dei	Trading Symbol TradingSymbol	NMTC
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	30811880	shares
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1619977	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5322493	usd
CY2024Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	410551	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	1793432	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	1726686	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	261477	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	263746	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	4085437	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	7312925	usd
CY2024Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	72841	usd
CY2023Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	89577	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	281833	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	169059	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	472486	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	525753	usd
CY2024Q2	us-gaap	Assets Assets	4912597	usd
CY2023Q3	us-gaap	Assets Assets	8097314	usd
CY2024Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	759260	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	685104	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	931700	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1107522	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	1690960	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	1792626	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	209910	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	55284	usd
CY2024Q2	us-gaap	Liabilities Liabilities	1900870	usd
CY2023Q3	us-gaap	Liabilities Liabilities	1847910	usd
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	27846722	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	27846722	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23928945	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23928945	shares
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	27847	usd
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	23929	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	74637698	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	68911778	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-71653818	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-62686303	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	3011727	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	6249404	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4912597	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8097314	usd
CY2024Q2	us-gaap	Revenues Revenues	825776	usd
CY2023Q2	us-gaap	Revenues Revenues	629906	usd
	us-gaap	Revenues Revenues	3180719	usd
	us-gaap	Revenues Revenues	1210661	usd
CY2024Q2	us-gaap	Cost Of Revenue CostOfRevenue	543904	usd
CY2023Q2	us-gaap	Cost Of Revenue CostOfRevenue	386240	usd
	us-gaap	Cost Of Revenue CostOfRevenue	2242114	usd
	us-gaap	Cost Of Revenue CostOfRevenue	947799	usd
CY2024Q2	us-gaap	Gross Profit GrossProfit	281872	usd
CY2023Q2	us-gaap	Gross Profit GrossProfit	243666	usd
	us-gaap	Gross Profit GrossProfit	938605	usd
	us-gaap	Gross Profit GrossProfit	262862	usd
	nmtc	Revenue From Collaboration RevenueFromCollaboration	1455188	usd
CY2024Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1881099	usd
CY2023Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1862389	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6057520	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5347234	usd
CY2024Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1194674	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1891512	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3951559	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5161322	usd
CY2024Q2	us-gaap	Operating Expenses OperatingExpenses	3075773	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	3753901	usd
	us-gaap	Operating Expenses OperatingExpenses	10009079	usd
	us-gaap	Operating Expenses OperatingExpenses	10508556	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2793901	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-3510235	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-9070474	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-8790506	usd
CY2024Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	26376	usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	41462	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	102959	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	66136	usd
CY2024Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2767525	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3468773	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8967515	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8724370	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-2767525	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-3468773	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8967515	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8724370	usd
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.1
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.2
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.35
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.52
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27352660	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17578871	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25746503	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16740546	shares
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	9604364	usd
CY2022Q4	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	300181	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-1732769	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	8171776	usd
CY2023Q1	nmtc	Stock Issued During Period Value Issuance Of Common Stock In Connection With Atthemarket Offering Program StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithAtthemarketOfferingProgram	928257	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	-183359	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	237628	usd
CY2023Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	98650	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-3522828	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	5532824	usd
CY2023Q2	nmtc	Stock Issued During Period Value Issuance Of Common Stock In Connection With Atthemarket Offering Program StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithAtthemarketOfferingProgram	1624399	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	-51366	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	296402	usd
CY2023Q2	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	12188	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-3468773	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	3921298	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	6249404	usd
CY2023Q4	nmtc	Stock Issued During Period Value Issuance Of Common Stock In Connection With Atthemarket Offering Program StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithAtthemarketOfferingProgram	1256271	usd
CY2023Q4	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	-37698	usd
CY2023Q4	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	308638	usd
CY2023Q4	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	13559	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	-3344900	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	4418156	usd
CY2024Q1	nmtc	Stock Issued During Period Value Issuance Of Common Stock In Connection With Atthemarket Offering Program StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithAtthemarketOfferingProgram	2094196	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	-148382	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	356858	usd
CY2024Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	11295	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-2855090	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	3854443	usd
CY2024Q2	nmtc	Stock Issued During Period Value Issuance Of Common Stock In Connection With Atthemarket Offering Program StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithAtthemarketOfferingProgram	1683439	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	-50519	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	338609	usd
CY2024Q2	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	46720	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-2767525	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	3011727	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8967515	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8724370	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	182664	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	136757	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1004105	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	834211	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	45571	usd
	nmtc	Noncash Lease Expense NoncashLeaseExpense	-86611	usd
	nmtc	Noncash Lease Expense NoncashLeaseExpense	-81567	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	410551	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-33237	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	66746	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	811989	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2269	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-85022	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	44787	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-62808	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-220581	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-1510104	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8344957	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9984048	usd
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	1473419	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	4500000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	83292	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	326497	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-83292	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	2700084	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5033906	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2552656	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	236599	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	234725	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	71574	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	110838	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4725733	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2207093	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-3702516	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-5076871	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5322493	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8160329	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1619977	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3083458	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	199385	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	97536	usd
	nmtc	Unpaid Deferred Issuance Costsoffset In Prepaids And Other Assets UnpaidDeferredIssuanceCostsoffsetInPrepaidsAndOtherAssets	67159	usd
	nmtc	Purchased Property And Equipment In Accounts Payable PurchasedPropertyAndEquipmentInAccountsPayable	34000	usd
	nmtc	Purchased Property And Equipment In Accounts Payable PurchasedPropertyAndEquipmentInAccountsPayable	26798	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-71700000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Management’s Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2024Q2	us-gaap	Advertising Expense AdvertisingExpense	45000	usd
	us-gaap	Advertising Expense AdvertisingExpense	110053	usd
CY2023Q2	us-gaap	Advertising Expense AdvertisingExpense	49492	usd
	us-gaap	Advertising Expense AdvertisingExpense	156131	usd
	nmtc	Number Of Days To Remedy Default NumberOfDaysToRemedyDefault	P90D
CY2024Q2	us-gaap	Royalty Expense RoyaltyExpense	37500	usd
CY2023Q2	us-gaap	Royalty Expense RoyaltyExpense	37500	usd
	us-gaap	Royalty Expense RoyaltyExpense	112500	usd
	us-gaap	Royalty Expense RoyaltyExpense	112500	usd
CY2021Q3	nmtc	Lease Space LeaseSpace	1162	sqm
CY2021Q3	us-gaap	Operating Leases Rent Expense Contingent Rentals OperatingLeasesRentExpenseContingentRentals	4241	usd
CY2022Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P2Y
	us-gaap	Operating Lease Payments OperatingLeasePayments	103795	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	100562	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	199385	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	97536	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	281833	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	169059	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	290090	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	184400	usd
CY2024Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y8M12D
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y4M24D
CY2024Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.074	pure
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.078	pure
CY2024Q2	nmtc	Lessee Operating Lease Liability To Be Paid Remainder Of Calendar Year LesseeOperatingLeaseLiabilityToBePaidRemainderOfCalendarYear	70243	usd
CY2024Q2	nmtc	Lessee Operating Lease Liability Payments Due Fiscal Year LesseeOperatingLeaseLiabilityPaymentsDueFiscalYear	66097	usd
CY2024Q2	nmtc	Lessee Operating Lease Liability Payments Due Two Year LesseeOperatingLeaseLiabilityPaymentsDueTwoYear	78945	usd
CY2024Q2	nmtc	Lessee Operating Lease Liability Payments Due Three Year LesseeOperatingLeaseLiabilityPaymentsDueThreeYear	81708	usd
CY2024Q2	nmtc	Lessee Operating Lease Liability Payments Due Four Year LesseeOperatingLeaseLiabilityPaymentsDueFourYear	34816	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	331809	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	41719	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	290090	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	80180	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	209910	usd
CY2024Q2	us-gaap	Inventory Gross InventoryGross	835492	usd
CY2023Q3	us-gaap	Inventory Gross InventoryGross	1202778	usd
CY2024Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	254638	usd
CY2023Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	343597	usd
CY2024Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	703302	usd
CY2023Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	180311	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	1793432	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	1726686	usd
CY2023Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	89577	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	16736	usd
CY2024Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	72841	usd
CY2024Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5578	usd
CY2023Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5578	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	16736	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	16736	usd
CY2024Q2	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	973398	usd
CY2023Q3	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	860737	usd
CY2024Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	973398	usd
CY2023Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	860737	usd
CY2024Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	500912	usd
CY2023Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	334984	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	472486	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	525753	usd
CY2024Q2	us-gaap	Depreciation Depreciation	57529	usd
	us-gaap	Depreciation Depreciation	165928	usd
CY2023Q2	us-gaap	Depreciation Depreciation	51380	usd
	us-gaap	Depreciation Depreciation	120021	usd
CY2024Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	779284	usd
CY2023Q3	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	874382	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	80180	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	129116	usd
CY2024Q2	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	72236	usd
CY2023Q3	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	104024	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	931700	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1107522	usd
	us-gaap	Payments For Fees PaymentsForFees	2000000	usd
CY2022Q3	us-gaap	Payment For Management Fee PaymentForManagementFee	3500000	usd
	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	3
	nmtc	Transaction Price Associated With The Development Agreement TransactionPriceAssociatedWithTheDevelopmentAgreement	5400000	usd
	nmtc	Fair Value Adjustment To The Transaction Price Of The Development Agreement And Amendment FairValueAdjustmentToTheTransactionPriceOfTheDevelopmentAgreementAndAmendment	100000	usd
	nmtc	Revenue From Collaboration RevenueFromCollaboration	1455188	usd
CY2022Q3	us-gaap	Deferred Revenue DeferredRevenue	1455188	usd
	us-gaap	Recognition Of Deferred Revenue RecognitionOfDeferredRevenue	-1455188	usd
CY2024Q2	us-gaap	Revenues Revenues	825776	usd
	us-gaap	Revenues Revenues	3180719	usd
CY2023Q2	us-gaap	Revenues Revenues	629906	usd
	us-gaap	Revenues Revenues	1210661	usd
CY2024Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	338609	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	296402	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1004105	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	834211	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum	0.13	pure
CY2024Q1	nmtc	Option Plan Shares OptionPlanShares	1051556	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	339000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1225669	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	469512	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.92
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.08
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.88
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2814096	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1708427	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.581	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	1.119	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.574	pure
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M6D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M6D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y9M18D
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.036	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.046	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.037	pure
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	127583	shares
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	69947	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	65000	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	521	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	232494	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	282172	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	120000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	521	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	289215	shares
CY2024Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	2713998	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y6M
	nmtc	Numberof Customerfor Revenue NumberofCustomerforRevenue	one
CY2024Q2	nmtc	Company Launch Ablation System And Sold To Concentration Risk Additional Customers CompanyLaunchAblationSystemAndSoldToConcentrationRiskAdditionalCustomers	two
CY2024Q2	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	0.20	pure
CY2024Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2023Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2022Q4	nmtc	Maximum Aggregate Common Stock Offering Price MaximumAggregateCommonStockOfferingPrice	14500000	usd
CY2022Q4	nmtc	Fixed Commission Rate FixedCommissionRate	0.03	pure
CY2023Q3	nmtc	Maximum Aggregate Common Stock Offering Price MaximumAggregateCommonStockOfferingPrice	2600000	usd
CY2023Q4	nmtc	Maximum Aggregate Common Stock Offering Price MaximumAggregateCommonStockOfferingPrice	4800000	usd
CY2024Q1	nmtc	Maximum Aggregate Common Stock Offering Price MaximumAggregateCommonStockOfferingPrice	9300000	usd
CY2024Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1419317	shares
	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	3748913	shares
CY2024Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1683439	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5033906	usd
CY2023Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1624399	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2552656	usd
CY2023Q2	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	51366	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	234725	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q2	nmtc	Revenue From Collaboration RevenueFromCollaboration		usd
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16740546	shares
CY2022Q4	nmtc	Stock Issued During Period Value Restricted Stock Unit Gross StockIssuedDuringPeriodValueRestrictedStockUnitGross		usd
CY2023Q1	nmtc	Stock Issued During Period Value Restricted Stock Unit Gross StockIssuedDuringPeriodValueRestrictedStockUnitGross		usd
CY2023Q4	nmtc	Stock Issued During Period Value Restricted Stock Unit Gross StockIssuedDuringPeriodValueRestrictedStockUnitGross		usd
CY2024Q1	nmtc	Stock Issued During Period Value Restricted Stock Unit Gross StockIssuedDuringPeriodValueRestrictedStockUnitGross		usd
CY2024Q2	nmtc	Stock Issued During Period Value Restricted Stock Unit Gross StockIssuedDuringPeriodValueRestrictedStockUnitGross		usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments		usd
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments		usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments		usd
	nmtc	Unpaid Deferred Issuance Costsoffset In Prepaids And Other Assets UnpaidDeferredIssuanceCostsoffsetInPrepaidsAndOtherAssets		usd
CY2023Q3	us-gaap	Deferred Revenue DeferredRevenue		usd
	us-gaap	Recognition Of Deferred Revenue RecognitionOfDeferredRevenue		usd
CY2024Q2	us-gaap	Deferred Revenue DeferredRevenue		usd
CY2023Q2	us-gaap	Deferred Revenue DeferredRevenue		usd
	nmtc	Revenue From Collaboration RevenueFromCollaboration		usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate		pure
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate		pure
CY2024Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised		usd
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised		usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised		usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised		usd
CY2024Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--09-30
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001500198

Files In Submission

Name	View Source	Status
nmtc-20240630_cal.xml	Edgar Link	unprocessable
0001213900-24-068633-index-headers.html	Edgar Link	pending
0001213900-24-068633-index.html	Edgar Link	pending
0001213900-24-068633.txt	Edgar Link	pending
0001213900-24-068633-xbrl.zip	Edgar Link	pending
ea0210819-10q_neuroone.htm	Edgar Link	pending
ea021081901ex10-1_neuroone.htm	Edgar Link	pending
ea021081901ex31-1_neuroone.htm	Edgar Link	pending
ea021081901ex31-2_neuroone.htm	Edgar Link	pending
ea021081901ex32-1_neuroone.htm	Edgar Link	pending
ea021081901ex32-2_neuroone.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nmtc-20240630.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
nmtc-20240630_def.xml	Edgar Link	unprocessable
nmtc-20240630_lab.xml	Edgar Link	unprocessable
nmtc-20240630_pre.xml	Edgar Link	unprocessable
ea0210819-10q_neuroone_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NMTC
NEUROONE MEDICAL TECHNOLOGIES Corp Stock $nmtc

2024 Q3 Form 10-Q Financial Statement

#000121390024068633 Filed on August 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NMTC NEUROONE MEDICAL TECHNOLOGIES Corp Stock $nmtc

2024 Q3 Form 10-Q Financial Statement

#000121390024068633 Filed on August 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NMTC
NEUROONE MEDICAL TECHNOLOGIES Corp Stock $nmtc